Evidence map›Paper›PMID 39707210›Full record

ArticleBMC medical imaging2024

Clinico-pathological factors and [

Nguyen Thi Phuong, Mai Hong Son, Mai Huy Thong, Le Ngoc Ha

Abstract read
In one paragraph

Article in BMC medical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nguyen Thi Phuong *Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
Mai Hong Son *Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
Mai Huy ThongDepartment of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
Le Ngoc HaDepartment of Nuclear Medicine, Hospital 108, Hanoi, Vietnam. doctorlengocha108@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIdentifying prognostic markers for clinical outcomes is crucial in selecting appropriate treatment options for patients with radioiodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC). The aim of this study was to investigate the prognostic value of clinico-pathological features and semiquantitative [ PATIENTS AND

methodsThis prospective cohort study included 110 consecutive RAI-R DTC patients who were referred for [

results[

conclusionsIn addition to classic clinico-pathological factors, the semiquantitative [

Indexed as

Fluorodeoxyglucose F18Iodine RadioisotopesPositron Emission Tomography Computed TomographyProgression-Free SurvivalRadiopharmaceuticalsThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPrognosisProspective StudiesTumor BurdenYoung AdultFluorodeoxyglucose F18Iodine RadioisotopesRadiopharmaceuticals[18F]FDG PET/CTMTVProgression-free survivalRadioiodine-refractory differentiated thyroid cancerSemiquantitative [18F]FDG parametersTLG

Identifiers

PMID39707210
PMCPMC11661047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.